<DOC>
	<DOCNO>NCT01258868</DOCNO>
	<brief_summary>Background : - Recent research show cause immune response tumor cell may help slow stop growth tumor . One treatment come research involve collect modify cancer patient 's tumor cell laboratory , return cell patient vaccine encourage immune system respond . Researchers interested test tumor cell vaccine experimental drug call ISCOMATRIX , add vaccine order elicit strong immune response body . ISCOMATRIX approve sale use country use still experimental , though test use safely clinical study . Researchers also interested determine whether anti-inflammatory drug celecoxib improve body 's immune reaction give vaccine . Objectives : - To assess safety effectiveness tumor cell vaccine give ISCOMATRIX celecoxib treatment lung esophagus cancer . Eligibility : - Individuals least 18 year age primary small cell non-small cell lung cancer , esophageal cancer , pleural mesothelioma remove surgery . - Only individual whose tumor cell able produce tumor cell line vaccine development eligible treatment . Design : - Participants screen physical examination medical history , tumor tissue collect surgery determine whether tumor cell use produce vaccine . - Participants take celecoxib twice daily 7 day first tumor cell vaccination . Participants also leukapheresis collect blood cell test first vaccination . - Participants receive one vaccine ( may give two shot ) monthly 6 month , continue take celecoxib twice daily . One month 6th vaccine shot , participant another leukapheresis skin test . If test show participant respond vaccine , additional vaccine give every 3 month 2 year . - Participants physical exam lab test vaccination , blood sample image study every 3 month , skin test every 6 month . - Participants regular followup visit image study blood sample 5 year first vaccination , new tumor develop ... .</brief_summary>
	<brief_title>Tumor Cell Vaccines With ISCOMATRIX Adjuvant Celecoxib Patients Undergoing Resection Lung Esophageal Cancers Malignant Pleural Mesotheliomas</brief_title>
	<detailed_description>Background : - Cancer-testis ( CT ) antigens emerged attractive target cancer immunotherapy . Whereas lung esophageal cancer , thymic Neoplasms , primary thoracic sarcoma , well malignant pleural mesothelioma express variety CT antigens , primary vaccine-induced immune response antigens appear uncommon patient malignancy , possibly due low-level , heterogeneous antigen expression , inadequate vaccination strategy . - Because numerous CT antigen induce tumor cell DNA demethylating agent HDAC inhibitor , conceivable vaccination cancer patient autologous tumor cell expose chromatin remodel agent enhance anti-tumor immunity individual . - In order examine issue , patient resectable primary neoplasm involve lung , esophagus , pleura vaccinate autologous tumor cell expose exvivo decitabine radiation follow completion appropriate combine modality therapy . Vaccine administer conjunction ISCOMATRIX adjuvant oral celecoxib . Primary Objective : - To assess safety epigenetically modify autologous tumor cell vaccine conjunction celecoxib . Eligibility : - Patients histologically cytologically prove clinically evident primary pulmonary carcinoma sarcoma , esophageal cancer , thymic carcinoma malignant pleural mesothelioma undergo resection neoplasm . - Patients must 18 year old ECOG performance status 0 2 , adequate pulmonary cardiac function laboratory value within normal limit . Design : - Patients operable lung esophageal carcinoma/sarcoma , thymoma , thymic carcinoma malignant pleural mesothelioma undergo resection malignancy NCI . - Portions resect tumor transfer Thoracic Oncology Laboratory cell process establish cancer cell line . - Following recovery surgery appropriate adjuvant chemotherapy and/or radiation , patient vaccinate epigenetically-modified autologous tumor cell periodically 6 month conjunction oral celecoxib . - Systemic toxicity delay type hypersensitivity responses autologous tumor cell serologic response variety CT antigens assessed vaccination . - Patients follow routine staging scan disease recurrence . - As exact set comparison analysis perform determine follow completion trial , base limited number patient , analysis consider exploratory hypothesis generate rather definitive . - Approximately 120 patient accrue trial order obtain 30 evaluable patient .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Thymoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>ELIGIBILITY CRITERIA : INCLUSION CRITERIA PRIOR TO SURGERY ( SCREENING CONSENT ) : 1 . Patients resectable clinically evident histologically proven primary small cell nonsmall cell lung cancer , esophageal cancer , thymoma , thymic carcinoma , primary sarcoma chest , pleural mesothelioma eligible treatment . 2 . Patients intracranial metastasis , treat surgery radiation therapy may eligible study provide evidence active disease . 3 . Patients prior Decitabine exposure eligible study . 4 . Patients must ECOG performance status 0 2 . 5 . Patients must 18 year age old due unknown effect immunologic response germ cellrestricted gene product childhood adolescent development . 6 . Seronegative HIV antibody . Note : The experimental treatment evaluate protocol depend intact immune system . Patients HIV seropositive decrease immune competence thus may less responsive experimental treatment . 7 . Seronegative active hepatitis B , seronegative hepatitis C antibody . If hepatitis C antibody test positive , patient must test presence antigen RTPCR HCV RNA negative . 8 . Patients must aware neoplastic nature illness , experimental nature therapy , alternative treatment , potential benefit , risk . 9 . Patients must willing sign inform consent , undergo resection malignancy NCI , ensure vaccine development . INCLUSION CRITERIA FOR TREATMENT PHASE OF PROTOCOL ( STANDARD CONSENT ) : 1 . Patients must sign Screening Consent 2 . NCI Laboratory Pathology confirmation diagnosis primary small cell nonsmall cell lung cancer , esophageal cancer , thymoma , thymic carcinoma , primary sarcoma chest , pleural mesothelioma must obtain 3 . Patients initially render NED surgical resection must remain NED time treatment . 4 . Patients 3 intracranial metastasis , definitively treat surgery radiation therapy may eligible study , provide evidence active disease least 2 month requirement anticonvulsant therapy steroid follow treatment . 5 . Patients must ECOG performance status 0 2 . 6 . Patients must evidence adequate bone marrow reserve , hepatic renal function evidence follow laboratory parameter : Absolute neutrophil count great 1500/mm ( 3 ) Platelet count great 100,000/mm ( 3 ) Hemoglobin great 8g/dl ( patient may receive transfusion meet parameter PT within 2 second ULN Total bilirubin &lt; 1.5 time upper limit normal Serum creatin ine less equal 1.6 mg/ml creatinine clearance must great 70 ml/min/1.73M ( 2 ) . f. Seronegative HIV antibody . Note : The experimental treatment evaluate protocol depend intact immune system . Patients HIV seropositive decrease immune competence thus may less responsive experimental treatment . g. Seronegative active hepatitis B , seronegative hepatitis C antibody . If hepatitis C antibody test positive , patient must test presence antigen RTPCR HCV RNA negative . h. Patients must willing practice birth control four month follow treatment . . Patients must willing sign standard inform consent . EXCLUSION CRITERIA FOR TREATMENT PHASE OF PROTOCOL : 1 . Patients unable/unwilling undergo resection malignancy NCI exclude . 2 . Patients initially render NED combine modality therapy exhibit disease progression prior initiation vaccination exclude treatment portion study . 3 . Patients receive two systemic cytotoxic treatment regimens thoracic malignancy time vaccination commences exclude . 4 . Patients require corticosteroid ( inhale ) exclude . 5 . Patients life expectancy le 12 month exclude . 6 . Patients receive warfarin anticoagulation , transfer agent enoxaparin dabigatran , anticoagulant hold 24 hour exclude . 7 . Patients uncontrolled hypertension ( &gt; 160/95 ) , unstable coronary disease evidence uncontrolled arrhythmia , unstable angina , decompensated CHF ( &gt; NYHA Class II ) , myocardial infarction within 6 month study exclude . 8 . Patients cardiac disease may exclude discretion PI follow consultation Cardiology consultant . 9 . Patients follow pulmonary function abnormality exclude : FEV , &lt; 30 % predict ; DLCO &lt; 30 % predict ( postbronchodilator ) ; pO2 &lt; 60 % pCO2 great equal 50 room air arterial blood gas . 10 . Pregnant and/or lactate woman exclude due unknown , potentially harmful effect immune response CTX antigens stem cell protein may express placenta , fetus , neonate . 11 . Patients active infection , include HIV , exclude , due unknown effect vaccine lymphoid precursor . 12 . Patients type primary immunodeficiency exclude study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>August 17, 2016</verification_date>
	<keyword>Mesothelioma</keyword>
	<keyword>Esophageal Cancer</keyword>
	<keyword>Lung Cancer</keyword>
	<keyword>Thoracic Malignancies</keyword>
	<keyword>Tumor Cell Vaccine</keyword>
</DOC>